Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Introduces Quantitative Multiplex Genomic Reference Standards

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Increasing the precision and utility of molecular assays for cancer genotype screening.

Horizon Diagnostics (HDx) has announced that it has launched its first Quantitative Multiplex DNA Reference Standard.

This standard is the first of its kind and is intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).

As multiplex assays and large tumor profiling projects become more common, standardization will be essential to enable confidence in experimental results.

To date, a significant challenge has been access to reliable, renewable external reference standards.

HDx’s novel Quantitative Multiplex DNA Reference Standard directly addresses this need by enabling researchers to quantify a range of detection thresholds for 11 cancer relevant mutations.

This is accomplished across complex samples in a single assay in the form of renewable material originating from precisely engineered cell lines.

The reference standard is available as genomic DNA and will be available in a matched formalin fixed paraffin embedded (FFPE) format in Q2, 2013.

The mutations were engineered into endogenous loci using Horizon’s proprietary genome editing platform, GENESIS™.

HDx has verified the Quantitative Multiplex DNA Reference Standard using digital PCR and the product has undergone extensive validation by external partners using NGS platforms such as Ion Torrent™.

Further validation is planned using MiSeq™ and Sequenom Mass Array™ Platforms.

“NGS workflows can be complex, typically involving extraction and amplification steps prior to sequencing and bioinformatic analysis. This gives scope for significant variability, which reduces confidence in the data generated, with the potential for some biomarkers being missed altogether,” Horizon’s VP of Products, Dr Paul Morrill, commented.

Dr Morrill continued, “To date, HDx has been successful in enabling laboratories with reliable and renewable singleplex reference standards. With the development and launch of this new Multiplex Standard, HDx is better able to support customers as they address the complexity of tumor genetics, driving towards better understanding of disease and ultimately better patient care.”

HDx will be actively expanding its list of Multiplex Reference Standards over the coming months.

The company is also open to working with clients seeking to develop custom standards with specific customer-defined genotypes and allelic frequencies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Acquires Sage Labs Inc. for $48M (£29M)
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company.
Wednesday, October 01, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.
Thursday, January 30, 2014
Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
Chairman’s healthcare industry career spans thirty years, encompassing all aspects of successful company growth and development.
Tuesday, January 14, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Discovery CEO Joins UKTI Delegation to India Led by David Cameron
Senior business and political leaders from India and Europe meet at Prabodhan Leaders’ Conclave.
Tuesday, November 26, 2013
Horizon Licenses ZFN Gene Editing Technology from Sigma-Aldrich
Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line generation services and creation of genetically-defined cell line products.
Tuesday, September 03, 2013
Scientific News
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!